《大行報告》美銀證券上調美東汽車(01268.HK)目標價至53元 評級「買入」
美銀證券發表研究報告指,美東汽車(01268.HK)宣布斥資37億元人民幣收購內地保時捷經銷商追星汽車,預期收購將令公司旗下保時捷門店數量翻倍,令其成為中國最大的保時捷經銷商之一。
報告指出,現時保時捷門店佔公司收入約18%,預期收購完成後佔比將提升至接近40%,考慮到保時捷的利潤率為其品牌組合中最高,對交易持樂觀態度,並重申「買入」評級,將2022至2023年淨利潤預測分別上調 6%及11%。
該行預期現時市場分散,美東汽車未來有更多收購機會,預期2024年每股盈利增幅可達25%,將目標價由47.5元上調至53元,以反映2023年預測市盈率約25倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.